Anzeige
Mehr »
Donnerstag, 23.07.2026 - Börsentäglich über 12.000 News
Aktie im Fokus: Gelingt jetzt der Turnaround?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A42711 | ISIN: US60785L3069 | Ticker-Symbol:
NASDAQ
22.07.26 | 19:39
2,810 US-Dollar
-5,07 % -0,150
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
MODULAR MEDICAL INC Chart 1 Jahr
5-Tage-Chart
MODULAR MEDICAL INC 5-Tage-Chart
ACCESS Newswire
370 Leser
Artikel bewerten:
(2)

Modular Medical, Inc.: Modular Medical Delivers Insulin to First Patients on Pivot Tubeless Insulin Patch Pump

First Patients Began Device Training and Insulin Delivery Today, Marking Transition to a Commercial Company

Pivot is the First Insulin Pump Designed to Address the Large, Underserved Population of Insulin-Dependent Adults Still Relying on Multiple Daily Injections, a Multibillion-Dollar Market

SAN DIEGO, CO / ACCESS Newswire / June 30, 2026 / Modular Medical, Inc. ("Modular Medical" or "the Company") (NASDAQ:MODD), a leader in innovative, patient-centric insulin delivery technology, today announced that the first patients have completed onboarding and training and are now actively using the Pivot tubeless insulin patch pump in real-world settings.

This milestone marks the transition of the Pivot pump from development into active patient use and represents a significant step in Modular Medical's commercialization strategy. The Company will now begin collecting real world utilization data and user feedback to support broader adoption and continued product deployment optimization.

"Today represents a defining moment for Modular Medical," said Jeb Besser, Chief Executive Officer of Modular Medical. "For the first time, patients are using Pivot to manage their insulin therapy, validating our vision of creating a simpler, more accessible pump solution for people who have historically remained on multiple daily injections. This is only the beginning of our efforts to address this substantial market opportunity, and we look forward to gathering real-world data and feedback, as we seek to scale adoption and achieve long-term growth."

For more information on the Pivot system, visit the dedicated site: PivotPump.com and YouTube Pivot Insulin Delivery System channel searchable @ModularMedical.

About Modular Medical

Modular Medical, Inc. (NASDAQ:MODD) is a commercial-stage medical device company that is commercializing the next generation of insulin delivery technology. Using its patented technologies, the Company seeks to eliminate the tradeoff between complexity and efficacy, thereby making top quality insulin delivery both affordable and simple to learn. Its mission is to improve access to the highest standard of glycemic control for people with diabetes taking it beyond "superusers" and providing "diabetes care for the rest of us."

Modular Medical was founded by Paul DiPerna, a seasoned medical device professional and microfluidics engineer. Prior to founding Modular Medical, Mr. DiPerna was the founder (in 2005) of Tandem Diabetes and invented and designed its t:slim insulin pump. More information is available at https://modular-medical.com.

Pivot is a trademark of Modular Medical in the United States. All other trademarks mentioned herein are the property of their respective owners.

Forward-Looking Statements

This press release contains forward-looking statements that are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to risks, trends, and uncertainties that could cause actual results to be materially different from the forward-looking statements contained in this press release, including but not limited to, the Company's ability to convert patients to use its Pivot pump product; successful development of Modular Medical's proprietary technologies, whether the market will accept Modular Medical's products and services, anticipated consumer demand for the Company's products, whether Modular Medical can successfully manufacture its products at high volumes, general economic, and industry or political conditions in the United States or internationally, as well as other risk factors and business considerations described in Modular Medical's SEC filings, including its annual report on Form 10-K. Any forward-looking statements in this press release should be evaluated in light of these important risk factors. In addition, any forward-looking statements included in this press release represent Modular Medical's views only as of the date of its publication and should not be relied upon as representing its views as of any subsequent date. Modular Medical assumes no obligation to update these forward-looking statements, except as required by law.

Company Contact:
Jeb Besser
Chief Executive Officer
Modular Medical, Inc.
IR@modular-medical.com

Investor Contact:
Valter Pinto, Managing Director
KCSA Strategic Communications
ModularMedical@KSCA.com

SOURCE: Modular Medical, Inc.



View the original press release on ACCESS Newswire:
https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/modular-medical-delivers-insulin-to-first-patients-on-pivot-tubeless-1184048

© 2026 ACCESS Newswire
Achtung, Korrektur!
Die Börsen laufen heiß. Trotz geopolitischer Krisen und steigender Zinsen klettern viele Indizes weiter Richtung Allzeithoch. Doch unter der Oberfläche zeigen sich erste Risse: Der Abverkauf bei Halbleiter-, KI- und Space-Aktien macht deutlich, wie schnell sich die Stimmung drehen kann.

Besonders gefährlich ist die aktuelle Gemengelage aus schwacher Saisonalität, dünner Liquidität in den Sommermonaten und historisch hohen Bewertungen. Selbst vermeintlich sichere Blue Chips sind inzwischen teuer bewertet und damit anfällig für Korrekturen. Gleichzeitig liefern technische Indikatoren erste Warnsignale. So werden viele Rekordstände nicht mehr bestätigt.

Für Anleger steigen die Risiken spürbar. Wer jetzt nicht genauer hinschaut, läuft Gefahr, auf dem falschen Fuß erwischt zu werden.

In unserem aktuellen Spezialreport zeigen wir fünf Aktien, bei denen die Abwärtsrisiken besonders hoch sind – und wo sich Gewinnmitnahmen oder sogar Short-Strategien anbieten könnten.

Jetzt den kostenlosen Report sichern – bevor die Korrektur Fahrt aufnimmt!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.